Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations

BACKGROUND: Several randomized controlled trials have suggested that adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) were associated with prolonged disease-free survival (DFS) in EGFR-mutated NSCLC patients after radical resection, comparing with chemotherapy or pl...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Qihua, Liu, Jun, Cai, Xiuyu, He, Miao, Li, Caichen, Liang, Hengrui, Cheng, Bo, Xia, Xiaojun, Guo, Minzhang, Liang, Peng, Zhong, Ran, Li, Feng, Yu, Ziwen, Zhao, Yi, Ou, Limin, Xiong, Shan, Li, Jianfu, Zhang, Jianrong, He, Jianxing, Liang, Wenhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674600/
https://www.ncbi.nlm.nih.gov/pubmed/35004243
http://dx.doi.org/10.21037/tlcr-21-649

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674600/
https://www.ncbi.nlm.nih.gov/pubmed/35004243
http://dx.doi.org/10.21037/tlcr-21-649

Ejemplares similares